Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients

• DOI: 10.1186/s12885-021-09069-9
• Publication Date: 2021-12-09T08:02:59Z
• Authors: Mitsuru Sugimoto; Tadayuki Takagi; Rei Suzuki; Naoki Konno; Hiroyuki Asama; Yuki Sato; Hiroki Irie; Yoshinori Okubo; Jun Nakamura; Mika Takasumi; Minami Hashimoto; Tsunetaka Kato; Ryoichiro Kobashi; Takuto Hikichi; Hiromasa Ohira
• Keywords: Pregabalin; Chemotherapy-Induced Peripheral Neuropathy; FOLFIRINOX

Abstract Background The prognosis of pancreatic cancer (PC) has been improved by new chemotherapy regimens (combination 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP)). Unfortunately, chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event these two regimens. efficacy pregabalin for CIPN reported in previous studies. However, the mirogabalin remains unknown. Thus, this study, we aimed to clarify which drug (mirogabalin pregabalin) was more valuable improving CIPN. Methods A total 163 PC patients who underwent FOLFIRINOX GnP between May 2014 January 2021 were enrolled. Among them, 34 diagnosed with Thirteen treated group), twenty-one (pregabalin group). Treatment compared groups. Results In both group group, grade at 2, 4, 6 weeks after initiation treatment showed significant improvement pretreatment grade. Notably, rate higher than (2 weeks: 84.6% (11/13) vs 33.3% (7/21), P value = 0.005; 4 weeks, 92.3% (12/13) 0.001). Conclusions Although effective CIPN, might be suitable first choice patients. Trial registration Not applicable